Biotron Limited · ASX:BIT
Biotron — Investor Presentation (November 2022)
13 slides from Biotron's investor presentation, Nov 11, 2022
Slide 1: Presentation to Investors (ASX cover letter)
Level 2, 66 Hunter Street Sydney NSW 2000 Tel: (61-2) 9300 3344 Fax: (61-2) 9221 6333 E-mail: pnightingale@biotron.com.au For personal use only Website: www.biotron.com.au 11 November 2022 The Manager Companies ASX Limited 20 Bridge Street Sydney NSW 2000 (13 pages by email) Dear Sir / Madam PRESENT
Slide 2: Biotron Limited Investor Update November 2022
For personal use only BIOTRON LIMITED (ASX:BIT) Investor Update November 2022
Slide 3: Forward Looking Statements
Forward Looking Statements For personal use only This presentation may contain forward‐looking statements with respect to the financial condition, results and business achievements/performance of Biotron Limited (ACN 086 399 144) and certain of the plans and objectives of its management. These state
Slide 4: Biotron Overview
Biotron Overview For personal use only • Clinical stage company with portfolio of small molecule drugs targeting viral diseases with major health problems: • HIV-1 , COVID-19, Hepatitis B virus and others • Unique approach to tackling virus infections • New class of anti-viral drugs that work in two
Slide 5: Key Achievements in 2022
Key Achievements in 2022 For personal use only • Completed enrolment of two Phase 2 HIV-1 clinical trials that build on positive results in previous clinical studies • Results expected mid-2023 • These studies are key to positioning of BIT225 for partnering • Demonstrated that BIT225 stops replicati
Slide 6: HIV-1 Clinical Program Update
HIV-1 Clinical Program Update For personal use only • Two Phase 2 HIV-1 clinical trials currently in progress at sites in Sydney, Australia (Holdsworth House, East Sydney Doctors and St Vincent’s Hospital, Darlinghurst) and in Thailand (Bangkok and Chiang Mai) • Both trials are fully recruited • Res
Slide 7: HIV-1 Market Opportunity
HIV-1 Market Opportunity • In 2021, despite availability of antiretroviral drugs (ART) - For personal use only • Over 38.4 million people globally were living with HIV • 1.5 million newly infected with the virus • An estimated 650,000 people died from AIDS-related illnesses. • The global HIV drug ma
Slide 8: SARS-CoV-2/COVID-19 Program Update
SARS-CoV-2/COVID-19 Program Update For personal use only • BIT225 has demonstrated ability to prevent COVID-19, reduce virus and stop the cytokine storm in a relevant, robust, industry-recognised animal model of disease* • A human COVID-19 study is in progress as a sub-study in Thailand in one of th
Slide 9: Ongoing Need for SARS-CoV-2/COVID-19 Anti-Viral Drugs
Ongoing Need for SARS-CoV-2/COVID-19 Anti-Viral Drugs For personal use only • Vaccines remain central to control of the pandemic but there is an unmet need for effective drugs to treat COVID • Uncertain global pandemic outlook • On-going risk of emergence of new SARS-CoV-2 variants • At risk populat
Slide 10: BIT225 Opportunity Summary
BIT225 Opportunity Summary For personal use only • BIT225 is a very important clinical asset for Biotron • Previous positive clinical trial data have significantly de-risked the program • Clear clinical development program designed to demonstrate to regulators and pharma how the drug may be used to
Slide 11: Outlook for 2023
Outlook for 2023 • 2023 will be an important year for this Company For personal use only • Results of three Phase 2 clinical trials expected in mid-2023 • Two Phase 2 HIV-1 clinical trials • Includes the COVID-19 sub-study that is in progress • New Phase 2 COVID clinical trial (subject to funding) •
Slide 12: Financial Information
Financial Information Key Financial Metrics For personal use only Ticker Code ASX: BIT Share Price (10/11/2022) A $0.035 Market Cap A $25 million 12 Month Trading Range A $0.033 – 0.111 A $0.68 million Cash Position (09/2022) + Anticipate receipt of R&D Tax refund of ~$1.4 m before end 2022 Board Mi
Slide 13: Biotron Limited contact
BIOTRON LIMITED For personal use only (ASX:BIT) Michelle Miller Managing Director mmiller@biotron.com.au www.biotron.com.au +61 412313329